CASI CASI Pharmaceuticals Inc.

+0.03  (+1%)
Previous Close 3.17
Open 3.17
Price To Book 2.94
Market Cap 306,294,566
Shares 95,717,052
Volume 203,650
Short Ratio
Av. Daily Volume 158,286

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 completed. Will not further development.
Cancer - Advanced/Metastatic Soft Tissue Sarcoma
Phase 2 initiated July 2012. Noted April 14, 2017 that further patient enrollment has been stopped.
Cancer - triple-negative breast cancer
Phase 1 trial to commence late-2019 or early 2020.
Multiple myeloma

Latest News

  1. CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
  2. CASI Pharmaceuticals To Present At The 2019 BIO International Convention
  3. CASI: Making headway towards commercialization
  4. CASI Pharmaceuticals Announces First Quarter 2019 Financial and Business Results
  5. CASI: Initiating coverage – Leveraging pharmaceutical opportunities in China and beyond
  6. Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down
  7. INVESTOR ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers
  8. CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics
  9. CASI Pharmaceuticals Announces The Appointment Of Wei-Wu He, Ph.D., Executive Chairman, To The Role Of Chief Executive Officer
  10. CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2018 Financial Results And Business Results
  11. CASI Pharmaceuticals Announces Exclusive Distribution Partner For Melphalan Hydrochloride For Injection (EVOMELA®) In China
  12. CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Registration Trial For MARQIBO®
  13. When Will CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Turn A Profit?
  14. Report: Developing Opportunities within Pure Storage, Flowers Foods, Cognex, CASI Pharmaceuticals, Ellie Mae, and Douglas Emmett — Future Expectations, Projections Moving into 2019
  15. CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Confirmatory Clinical Trial For ZEVALIN®
  16. CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference
  17. These 4 Healthcare Stocks Are Heating Up
  18. Do Institutions Own Shares In CASI Pharmaceuticals, Inc. (NASDAQ:CASI)?
  19. The 4 Healthcare Stocks To Watch On Monday
  20. CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)